PDE5 Inhibitor Combination Therapy for Erectile Dysfunction

Mechanism and Safety Concerns

The European Association of Urology and American Urological Association recommend against combining different PDE5 inhibitors due to the risk of additive vasodilatory effects, hypotension, and increased adverse events without proven additional benefit in patients with erectile dysfunction 1, 2, 3, 4
Tadalafil and vardenafil work through the same mechanism, inhibiting phosphodiesterase type 5 (PDE5), which prevents the breakdown of cyclic GMP, leading to smooth muscle relaxation and vasodilation in patients with erectile dysfunction 1
The most common adverse events with PDE5 inhibitors include headache, flushing, dyspepsia, nasal congestion, and dizziness, which would be amplified with concurrent use in patients with erectile dysfunction 2, 3

The American College of Physicians recommends choosing a single PDE5 inhibitor based on individual patient preferences, including ease of use, cost, and adverse effects profile, with a strength of evidence rated as moderate 5
Current guidelines from the European Association of Urology (2025) and American Urological Association (2018) do not support combining different PDE5 inhibitors, with a strength of evidence rated as high 2, 3, 4

The American Urological Association recommends verifying proper use of tadalafil, ensuring the patient is using it correctly with adequate sexual stimulation, as incorrect use accounts for many treatment failures, with a strength of evidence rated as moderate 2, 3
The European Association of Urology suggests considering dose optimization, such as switching to on-demand higher-dose tadalafil (10-20 mg) or switching to a different single PDE5 inhibitor like vardenafil, if daily tadalafil 5 mg is insufficient, with a strength of evidence rated as low 4, 2
The American Urological Association recommends evaluating for testosterone deficiency, as men with erectile dysfunction and low testosterone respond better to PDE5 inhibitors when combined with testosterone therapy rather than combining two PDE5 inhibitors, with a strength of evidence rated as moderate 2, 3

The European Association of Urology suggests considering switching between PDE5 inhibitors rather than combining them, though evidence for switching is limited, with a strength of evidence rated as low 4
The American Urological Association recommends evaluating for other therapies such as intracavernous injection therapy, vacuum erection devices, or low-intensity shockwave therapy, with a strength of evidence rated as moderate 4, 2
The European Association of Urology suggests assessing for underlying conditions that may impair response, including inadequate testosterone levels, severe vascular disease, or psychological factors, with a strength of evidence rated as moderate 4, 2

The American College of Physicians states that concurrent or intermittent use of nitrates in any form remains an absolute contraindication for all PDE5 inhibitors, including both tadalafil and vardenafil, due to the risk of severe hypotension, with a strength of evidence rated as high 5, 2